Meeting
2017 ASCO Annual Meeting
A randomized phase II trial of abiraterone, olaparib or abiraterone + olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair defects.
Authors
Zachery Reichert
University of Michigan, Ann Arbor, MI
Zachery Reichert , Benedito A. Carneiro , Stephanie Daignault-Newton , Amanda Sullivan , Felix Yi-Chung Feng , Todd Matthew Morgan , Scott A. Tomlins , Arul M. Chinnaiyan , Maha Hussain
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary (Prostate) Cancer
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Prostate Cancer - Advanced Disease
Clinical Trial Registration Number
NCT03012321
Citation
J Clin Oncol 35, 2017 (suppl; abstr TPS5086)
DOI
10.1200/JCO.2017.35.15_suppl.TPS5086
Abstract #
TPS5086
Poster Bd #
160a
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
A phase II single-arm trial of niraparib in platinum-sensitive metastatic castration-resistant prostate cancer with DNA repair defects (PLATPARP).
First Author: Vivek Narayan
Poster
2020 Genitourinary Cancers Symposium
TALAPRO-1: A phase II study of talazoparib (TALA) in men with DNA damage repair mutations (DDRmut) and metastatic castration-resistant prostate cancer (mCRPC)—First interim analysis (IA).
First Author: Johann S. De Bono
Poster
2023 ASCO Genitourinary Cancers Symposium
A phase II study of rucaparib monotherapy in nonmetastatic, hormone-sensitive prostate cancer (nmHSPC) with “BCRAness” genotype (ROAR).
First Author: Kamal Kant Kant Sahu
Poster
2022 ASCO Annual Meeting
BRCAAWAY: A randomized phase 2 trial of abiraterone, olaparib, or abiraterone + olaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) with DNA repair defects.
First Author: Maha H. A. Hussain